All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The clinical efficacy of CAR T-cell technology has been proven in the setting of human cancer, but there are many limitations to accessing this technology, such as cytokine release syndrome (CRS), the immunosuppressive mechanism in the tumor microenvironment, and T-cell exhaustion. shRNA provides a fast and efficient means of knocking down gene expression and the possibility of prolonged gene silencing. The introduction of shRNA cassettes into a CAR vector will help address the several current unmet needs in CAR T-cell therapy and empower the potential of CAR-T cell immunotherapies. At Creative Biolabs, our Research and Development Team is actively dedicated to developing safe and effective treatments for a range of different cancers. We utilize shRNA technology to improve the effect of CAR-T cells and expand the application of CAR-T therapy.
Creative Biolabs provides one-stop shRCAR cell development services. We can clone your desired shRNA sequences into our custom-designed CAR vectors. Plasmid DNA preparation, virus packaging, and shRCAR cell generation can be purchased upon finishing the designs of shRCAR vectors.
There are two modes of service:
Creative Biolabs can design and perform a full range of validation assay services, such as the identification of silenced targets in CAR-T cells, cytokine release test, cytotoxicity test, and cell proliferation test.
contact us for custom shRCAR services.
Data 1: PD-1 silence to improve the proliferation and anti-tumor effect of CAR-T cells
The gene of interest: PD-1
CAR: CD19 CAR and PSCA CAR
Vector: Lentivirus vector
CAR generation: Third-generation CAR-T cells
Fig.1 PD-1 silence enhances anti-tumor efficacy in CAR-T cells.1
Data 2: GM-CSF silence to improve the safe of CAR-T cells without damaging the cytotoxicity
The gene of interest: GM-CSF
CAR: CD19 CAR
Vector: Lentivirus vector
CAR generation: Second-generation CAR-T cells
Fig.2 GM-CSF silence reduces the secretion of multiple inflammatory cytokines without damaging the cytotoxicity.2
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION